Engineered T-Cell Delivery Through CSF for CNS Tumor Access
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor-specific T cell therapies for treating central nervous system cancers, such as high-grade malignant glioma, face challenges with insufficient tumor-specificity, activity duration, and access, limiting their therapeutic efficacy.
Innovation Solution
Administering engineered T cells, such as CAR T cells or TCR-engineered T cells, directly to the cerebrospinal fluid (CSF) to target tumor antigens, allowing large volumes of T cells to access and treat both primary and secondary CNS malignancies, including those originating from other body parts, through methods like intraventricular or intracanal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If T cells are administered systemically for treating CNS cancers, then T cell availability increases, but T cell access to tumor sites remains insufficient due to blood-brain barrier and anatomical constraints
Solution Approach 1:
The patent uses the cerebrospinal fluid (CSF) as an intermediary medium to deliver T cells directly to the CNS tumor sites. By infusing T cells into the ventricular system or spinal canal, the cells travel through the CSF circulation to reach tumors throughout the CNS, overcoming the blood-brain barrier constraint while maintaining adequate T cell access to tumor sites
Solution Approach 2:
The patent transitions from systemic (systemic circulation) to local (CSF space) administration. This dimensional change in delivery route allows T cells to bypass the blood-brain barrier and directly access the CNS tumor microenvironment through the CSF pathway, simultaneously achieving both high availability and effective access
2Ease of operation
If conventional T cell therapies are used, then treatment simplicity is maintained, but tumor-specificity and activity duration remain insufficient
Solution Approach 1:
The patent modifies T cell parameters through genetic engineering to enhance tumor-specificity. By introducing chimeric antigen receptors (CARs) or tumor-specific T cell receptors (TCRs) into T cells, the patent changes the cellular parameters (receptor specificity, signaling capacity, persistence) to achieve reliable tumor targeting while maintaining the relatively simple adoptive cell therapy framework
3Quantity of substance
If large volumes of T cells are administered to ensure adequate dosing, then T cell coverage improves, but administration complexity increases due to volume constraints
Solution Approach 1:
The patent segments the administration process into two phases: (1) infusion of T cells into the ventricular system or spinal canal (simple initial step), and (2) natural CSF circulation distributing cells throughout the CNS (passive distribution phase). This segmentation allows large T cell doses to be administered through simple procedures while the CSF system handles the distribution complexity
Data Source
AI summary
An improved method of treating cancers with engineered T cells is described.